Research News
A new BrightFocus-funded study found that identifying disruptive sleep patterns may help identify people at risk of Alzheimer’s disease up to seven years prior to end of life.
A promising new treatment for individuals suffering from stroke, concussion, and traumatic brain injury, known risk factors for dementia, has received approval from the U.S. Food & Drug Administration to move into Phase 2 clinical trials. Learn more.
Learn how our funded scientists are advancing new ways of diagnosing Alzheimer’s disease earlier and more accurately.
Alzheimer’s Disease Research, a BrightFocus Foundation program, joined over 4,500 scientists, physicians, and industry leaders from 70 countries at the annual International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD) in Lisbon, Portugal. Read our key takeaways.
The company behind the first-of-its-kind blood-based screening test for Alzheimer’s disease—rooted in pivotal early BrightFocus support—has received a $15 million investment that will broaden access to the blood test for patients and doctors.
A National Institute on Aging senior investigator breaks down amyloid trials: what went wrong and what must come next.
Immune cells undergo non-inherited genetic changes that are associated with higher Alzheimer’s risk.
A new study asks the question: what if we could reverse the damage caused by Alzheimer’s disease-related proteins like tau? Learn more.
The anti-amyloid therapy will go off the market later this year.
In a new BrightFocus-funded study, researchers found an association between alterations in circadian rest-activity rhythms and risk of frailty incidence in older adults.
